Study Links GLP-1 Drugs to 50% Lower Cancer Progression Risk in Lung Patients
Updated
Updated · NBC News · May 21
Study Links GLP-1 Drugs to 50% Lower Cancer Progression Risk in Lung Patients
7 articles · Updated · NBC News · May 21
More than 10,000 cancer patients in a TriNetX database study who started GLP-1 drugs after diagnosis were generally less likely to see tumors metastasize than matched patients taking DPP-4 inhibitors.
A statistically significant reduction appeared in four cancers—non-small cell lung, breast, colorectal and liver—with lung patients 50% less likely to progress to stage 4 and breast patients 43% less likely.
Tumors with higher GLP-1 receptor levels were less likely to metastasize, giving researchers a possible explanation for the effect beyond better control of diabetes or obesity.
Because the study was observational and not yet peer-reviewed, doctors said randomized trials are still needed; for now, the main takeaway is that GLP-1s appear safe for diabetes or weight loss use during cancer treatment.
If GLP-1s can fight cancer, will only the wealthy be able to afford this protection?
Could popular weight-loss drugs become our next major weapon against cancer's spread?
GLP-1 Drugs and Cancer: Emerging Evidence, Key Biases, and the Urgent Need for Randomized Trials in 2026
Overview
Recent real-world data suggest that GLP-1 receptor agonists (GLP-1s), drugs mainly used for diabetes and obesity, may help reduce the risk and progression of certain cancers. Evidence shows GLP-1s could lower the spread of obesity-related cancers like lung, breast, colorectal, and liver cancer. This effect may be linked to how GLP-1 receptors influence cancer survival, hinting that the GLP-1 pathway plays a role in cancer development. Additionally, GLP-1s show promise in preventing some cancers, such as colorectal cancer, making them a potential new tool in cancer prevention and treatment.